STADA and Xbrane launch ranibizumab to support patient access in Europe - Ranibizumab biosimilar is being launched in major European markets - Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane, marking Xbrane’s first commercial launch and ...
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) - Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) ...
Adalvo and STADA extend their strategic partnership - Strategic partnership in Europe extended to cover five additional molecules in therapeutic categories including oncology and diabetes - Adalvo CEO Anil Okay: “These new agreements demonstrate the significance of the strategic partnership we have built with STADA, in the last couple of years. We take ...
Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe - Launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in Europe - Follows initial introduction of adalimumab in ninecountries: ...
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis® - European Commission grants pan-EU marketing authorization for Ximluci® biosimilar referencing Lucentis® (ranibizumab) - Paves way for European ...
STADA sets standard in Specialty by launching the first medicine authorized in the EU for treating rare kidney disease - Germany is STADA’s lead launch market for EU’s first authorized treatment for a rare kidney disease immunoglobulin A ...
Strong in-market performance leads STADA to double-digit growth - Continued strong organic market-share gains across key European markets, supported by several launches - Adjusted Group sales advance by 15% while adjusted EBITDA improve by 23% in first half of 2022 - STADA CEO Peter Goldschmidt: “In ...
STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy - The European Commission (EC) has granted conditional marketing authorization for Kinpeygo® for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a ...
STADA Health Report 2022: Europe experiencing worsening health conditions - Self-assessed burnout rates at all-time high; stress levels have increased; more than one in three are struggling with sleep; appreciation for healthcare systems decreases after Covid high - STADA Health Report 2022: ...
STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab - Offers a comprehensive range of presentations to the EU adalimumab biosimilars market - Adalimumab marks the first molecule ...
STADA set to expand Specialty portfolio after positive CHMP opinion on KinpeygoTM orphan medicine for IgA nephropathy - CHMP within the European Medicines Agency issues positive opinion on KinpeygoTM, a novel oral formulation of budesonide, for ...
Alvotech and STADA pave way to launching HUKYNDRA®(AVT02), a citrate-free, high-concentration biosimilar to Humira® by resolving European patent dispute with AbbVie - Upon launch, HUKYNDRA® will be one of two citrate-free, high-concentration ...
Ignis Therapeutics and STADA partner for apomorphine subcutaneous injection in China - Ignis and STADA’s Britannia sign exclusive licensing agreement to develop and commercialize subcutaneous apomorphine in mainland China, Hong Kong and Macau - Dr. Eileen Long, CEO of Ignis: “Ignis is now ...
STADA extends European oncology offering by launching lenalidomide - STADA introduces lenalidomide generic alternative to Revlimid in more than a dozen European countries - Market entry with the multiple myeloma treatment ahead of patent expiry adds to a comprehensive offering for oncologists and their ...
Bioglan and STADA partner to increase capacity to meet rising demand for Parkinson’s treatment - Reig Jofre’s Bioglan subsidiary and STADA are investing EUR3 million to expand Bioglan’s facilities with a highly technological production line ...
Bioglan and STADA partner to increase capacity to meet rising demand for Parkinson’s treatment - Reig Jofre’s Bioglan subsidiary and STADA are investing EUR 3 million to expand Bioglan’s facilities with a highly technological production line ...
NTC and STADA partner for a portfolio of ophthalmic products in the MENA region - NTC is granting to STADA license and distribution rights for certain proprietary ophthalmic products in the MENA region - The licensed products are intended to address ...
STADA continues to outpace the market in H1 and strengthens basis for further growth - STADA achieved 5% adjusted sales growth to EUR1.5 billion in the first half of 2021 versus a market decline of -1.8%. - The successful integration of several ...
STADA and Sanofi strike consumer healthcare distribution agreement in selected countries in Europe - Sanofi will distribute its consumer healthcare portfolio through STADA in 20 countries across Europe, including the Nordic countries, the ...
STADA and partner Xbrane advance biosimilar ranibizumab candidate - Primary endpoint met in pivotal ‘Xplore’ ranibizumab comparability trial; regulatory submissions in EU and US planned during second half of 2021 - If approved, ranibizumab would take STADA’s biosimilars portfolio into the ...
STADA further grows European Consumer Healthcare portfolio by acquiring 16 well-established brands from Sanofi - STADA is acquiring from Sanofi well-established consumer healthcare brands across 13 countries , including France, Germany, Italy, Poland ...
